Riskpilot← Back to searchSign inGet full accessØJENLÆGE KLAUS TRIER ApS
APSActiveCVR 18310902Tingskiftevej 6Medical specialists activities · NACE 8622Est. 19941 employees
Revenue 2024
DKK -82K
+298% vs 2023
EBITDA margin
100.0%
-7% vs 2023
Equity ratio
71.9%
Financial strength
Net profit 2024
DKK -65K
+56% vs 2023
| Revenue | DKK -82K | +298% |
| EBITDA | DKK -82K | -7% |
| Net profit | DKK -65K | +56% |
| Total assets | DKK 390K | -15% |
| Equity | DKK 280K | -19% |
| Employees | 1 | — |
Legal name
ØJENLÆGE KLAUS TRIER ApS
CVR number
18310902
Legal form
Anpartsselskab
NACE code
8622 · Medical specialists activities
Founded
30. december 1994
Share capital
DKK 200.000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør alene.
Company purpose
Selskabets formål er at drive speciallægevirksomhed, medicinsk forskning og virksomhed, der er naturligt forbundet hermed.
Address
Tingskiftevej 6
Phone
+4539625618
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 51 | 9 | -18 | -21 | -82 |
| Staff expenses | -320 | -319 | -319 | -56 | -0 |
| EBITDA | -269 | -310 | -337 | -77 | -82 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | -269 | -310 | -337 | -77 | -82 |
| Net financials | -9 | 125 | 59 | -72 | 17 |
| Profit before tax | -278 | -185 | -278 | -149 | -65 |
| Tax | -0 | -0 | -0 | -0 | -0 |
| Net profit | -278 | -185 | -278 | -149 | -65 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 1.051 | 812 | 529 | 457 | 390 |
| Equity | 957 | 773 | 495 | 346 | 280 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 94 | 40 | 34 | 111 | 110 |
| Total debt | 94 | 40 | 34 | 111 | 110 |
EBITDA margin
-8226800.0%
This company
15.8%
Market median
-52068454% vs market
20202024
Equity ratio
71.9%
This company
38.2%
Market median
+88% vs market
20202024
Return on equity
-23.3%
This company
18.4%
Market median
-227% vs market
20202024
Net profit margin
-6535300.0%
This company
8.1%
Market median
-80682816% vs market
20202024
Asset turnover
-0.21×
This company
1.12×
Market median
-119% vs market
20202024
Debt / equity
0.39×
This company
0.62×
Market median
+37% vs market
20202024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
VE Founder | Founder | 1994 |
ST Founder | Founder | 1994 |
| Former (1) | ||
LS | Audit | 1994 – 1997 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 33.33–49.99% | 1994 | |
| Individual | 10–14.99% | 5–9.99% | 1994 | |
| Individual | 10–14.99% | 5–9.99% | 1994 | |
| Individual | 10–14.99% | 50–66.65% | 1994 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ØJENLÆGE KLAUS TRIER ApS 
TRIER PHARM ApSBoard members of ØJENLÆGE KLAUS TRIER ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vilma Edith Hansen | Founder | 0 companies |
| Svend Trier | Founder | 0 companies |
| Lars Skovgaard-Sørensen | Audit | 0 companies |